Glipizide Dose Equivalents to Other Sulfonylureas
The approximate dose equivalents are: glipizide 5 mg ≈ glyburide 2.5-3 mg ≈ glimepiride 1-2 mg, with glyburide being roughly twice as potent as glipizide on a milligram basis.
Dose Conversion Ratios
When switching between second-generation sulfonylureas, the following equivalencies apply based on clinical research:
Glipizide to Glyburide
- Glipizide 10 mg daily ≈ Glyburide 5 mg daily (2:1 ratio)
- A controlled crossover study demonstrated glyburide was twice as potent on a weight basis compared to glipizide, with mean final doses of glyburide 15.4 mg versus glipizide 29.7 mg achieving similar glycemic control 1
Glipizide to Glimepiride
- Glipizide 20-40 mg daily ≈ Glimepiride 1-2 mg daily (approximately 20:1 ratio)
- Clinical equivalence data suggests 1 mg glimepiride equals approximately 40 mg gliclazide or 1.25 mg glibenclamide (glyburide), making glimepiride significantly more potent than glipizide 2
Practical Switching Guidelines
When converting between sulfonylureas 3:
From Glipizide:
- To glyburide: Divide glipizide dose by 2 (e.g., glipizide 10 mg → glyburide 5 mg)
- To glimepiride: Divide glipizide dose by 20 (e.g., glipizide 20 mg → glimepiride 1 mg)
Important Caveats:
- Glyburide is generally not recommended in chronic kidney disease due to higher hypoglycemia risk 3
- Glipizide and glimepiride should be initiated conservatively in renal impairment to avoid hypoglycemia 3
- Monitor fasting glucose closely for 1-2 weeks after any switch, as hypoglycemia risk varies significantly between agents 4
Dose-Response Considerations
The maximum recommended doses often exceed the most effective doses 5:
- Glipizide: Maximum 40 mg/day (IR) or 20 mg/day (ER), but most effective dose is 20 mg/day (IR) or 5 mg/day (ER)
- Glyburide: Maximum 20 mg/day, but most effective dose is 2.5-5 mg/day
- Glimepiride: Maximum and effective dose both 4-8 mg/day
Prescribing at effective rather than maximum doses minimizes adverse events, particularly hypoglycemia and potential cardiovascular risks 5.
Safety Differences Between Agents
Recent cardiovascular outcomes data shows meaningful differences 6:
- Glipizide had the highest 5-year MACE-4 risk at 9.1% (risk ratio 1.13 vs DPP-4 inhibitors)
- Glimepiride showed intermediate risk at 8.6% (risk ratio 1.07)
- Glyburide showed lowest risk at 8.4% (risk ratio 1.04), though still not recommended due to hypoglycemia concerns
Glimepiride is the preferred sulfonylurea when this class is indicated, as it demonstrates cardiovascular safety and is not associated with weight gain or increased hypoglycemia compared to other sulfonylureas 3, 5.